We are excited to announce that Biocytogen will exhibit at the 6th mRNA-Based Therapeutics Summit from July 20th - 22nd. Major acquisitions and investments in the mRNA field are driving growth, with assets in vivo CAR-T, gene editing, and cancer immunotherapies demonstrating increasing clinical promise and commercial potential. Come visit our booth to learn more about how our target-humanized mouse models are driving innovative drug discovery!
What is the 6th mRNA-Based Therapeutics Summit
The 6th mRNA-Based Therapeutics Summit is a premier meeting for mRNA professionals. 250+ industry leaders gather to discuss the latest breakthroughs and technologies, making this a fantastic platform for collaboration opportunities. This year’s program covers everything from new data to next-gen designs, spread across three tracks: Discovery, Pre-Clinical & Clinical Development, and Manufacturing & CMC.
Event Overview
Date: July 20th - 22nd, 2026
Venue: The Westin Boston Seaport District, 425 Summer St, Boston, MA 02210
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
